Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Projected to Grow at 10.9% CAGR, Reaching $3.33 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Industry Market Size Be by 2025?
In recent times, the market size for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) testing has experienced a fast-paced expansion. Anticipated to expand from $1.98 billion in 2024 to $2.2 billion in 2025, the market will observe a compound annual growth rate (CAGR) of 11.1%. The significant growth in the past is tied to the rise in antibiotic resistance, increased awareness efforts, educational initiatives, and policy shifts.

What's the Long-Term Growth Forecast for the Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Size Through 2029?
The market size for testing chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) is predicted to witness swift expansion in the coming years. By 2029, it is anticipated to reach $3.33 billion, with a compound annual growth rate (CAGR) of 10.9%. The anticipated growth during the forecast period could be driven by advancements in telemedicine and telehealth, personalized medical strategies, the enlargement of point-of-care testing, as well as population health management strategies. The forecast period will also see significant trends such as the growth of rapid point-of-care testing, customized testing methods, platforms for testing multiple diseases, and community-centered testing and outreach programs.

View the full report here:
https://www.thebusinessresearchcompany.com/report/chlamydia-trachomatis-ct-and-neisseria-gonorrhoeae-ng-testing-global-market-report

What Are the Key Growth Drivers Fueling the Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Expansion?
The escalating incidence of sexually transmitted infections (STIs) is anticipated to drive the expansion of the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market in the future. STIs are illnesses caused by bacteria, viruses, or parasites that are transmitted through sexual contact. A rise in STIs can be attributed to inadequate sex education, increased sexual activity, stigma, and various barriers. Tests for Chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) play a critical role in the detection and control of sexually transmitted infections (STIs), by enabling early diagnosis, treatment, and avoidance of transmission. For instance, as per the World Health Organization's July 2023 reports, an intergovernmental organization based in Switzerland, globally, more than 1 million new STIs are contracted daily and an estimated 374 million new infections occur every year with one of four treatable STIs. Consequently, the rising incidents of sexually transmitted infections are fuelling the growth of the CTNG testing market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=14667&type=smp

What Are the Key Trends Driving Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Growth?
Leading enterprises within the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market are investing in the creation of advanced testing procedures, like the BD COR MX/PX System, a high-capacity infectious disease molecular diagnostic device aimed at addressing the growing demand for precise, effective and scalable testing solutions to fight the growing concern of sexually transmitted infections. The BD COR MX/PX System is an advanced lab device contrived to promptly and proficiently scrutinize a large volume of specimens for the occurrence of infectious diseases. For example, In May 2022, Becton Dickinson and Company, an American medical device corporation, introduced its new, entirely automated, high-capacity infectious disease molecular diagnostic platform, known as the BD COR MX/PX System, intended to simplify workflow in extensive labs that handle numerous infectious disease examinations including chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing. The system automates the entire process from receiving samples to delivering results through robotics and software algorithms, potentially reducing waiting times for results and enhancing efficiency. It also provides automation, high-throughput facility, dual DNA targets, and a modular and scalable design.

How Is the Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Segmented?
The chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market covered in this report is segmented -

1) By Test Type: Laboratory, Point Of Care Testing
2) By Product: Assays And Kits, Instruments Or Analyzers
3) By Technology: Isothermal Nucleic Acid Amplification Technology, Polymerase Chain Reaction, Immunodiagnostics, Other Technologies
4) By End User: Diagnostic Laboratories, Hospitals And Clinics, Other End Users

Subsegments:
1) By Laboratory: Nucleic Acid Amplification Tests (NAAT), Polymerase Chain Reaction (PCR) Tests, Enzyme-Linked Immunosorbent Assay (ELISA), Immunofluorescence Assay (IFA), Culture Tests, Direct Fluorescent Antibody (DFA) Tests
2) By Point Of Care Testing: Rapid Diagnostic Tests (RDT), Lateral Flow Assays, Immunochromatographic Tests, Self-Testing Kits, Loop-Mediated Isothermal Amplification (LAMP), Microfluidics-Based Tests

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=14667&type=smp

Which Companies Are Leading the Charge in Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Innovation?
Major companies operating in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthineers, Becton Dickinson and Company, Grifols SA, Hologic Inc., PerkinElmer, bioMérieux, Sysmex Corporation, Bio-Rad Laboratories, QIAGEN, Quidel Corporation, DiaSorin, Cepheid, Seegene Inc., Meridian Bioscience Inc., Sekisui Diagnostics, J. Mitra & Co. Pvt. Ltd., Atlas Medical, Hardy Diagnostics, Molbio Diagnostics Pvt. Ltd., NG Biotech

Which Regions Are Leading the Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market in Revenue?
North America was the largest region in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market in 2024. The regions covered in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=14667

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.